aTyr Pharma to Present at 35th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 4, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the 35^th Annual J.P. Morgan Healthcare Conference to be held at the Westin St. Francis in San Francisco, CA from January 9 – 12, 2017.  

John Mendlein, Ph.D., CEO, will provide an overview of the Company during a presentation at 9:00 a.m. PT on Thursday, January 12, 2017. The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com.  An audio replay will be available for at least 30 days following the initial presentation webcast. 

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 80 issued or allowed patents and over 230 pending patent applications that are owned or exclusively licensed by aTyr, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.

Contact:
Mark Johnson
Sr. Director, Investor Relations
[email protected]
858-223-1163

SOURCE aTyr Pharma, Inc.

Related Links

http://www.atyrpharma.com